MOBIC Drug Patent Profile

When do Mobic patents expire, and when can generic versions of Mobic launch?

Mobic is a drug marketed by Boehringer Ingelheim and is included in one NDA.

The generic ingredient in MOBIC is meloxicam. There are twenty-two drug master file entries for this compound. Forty-five suppliers are listed for this compound. Additional details are available on the meloxicam profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Mobic

A generic version of MOBIC was approved as meloxicam by AVONDALE PHARMS on June 1^st, 2004.

Summary for MOBIC

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	112
Drug Prices:	Drug price information for MOBIC
What excipients (inactive ingredients) are in MOBIC?	MOBIC excipients list
DailyMed Link:	MOBIC at DailyMed

See drug prices for MOBIC

See drug sales revenues for MOBIC

US Patents and Regulatory Information for MOBIC

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Boehringer Ingelheim	MOBIC	meloxicam	TABLET;ORAL	020938-001	Apr 13, 2000		DISCN	Yes	No
Boehringer Ingelheim	MOBIC	meloxicam	TABLET;ORAL	020938-002	Aug 23, 2000		DISCN	Yes	No

EU/EMA Drug Approvals for MOBIC

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Norbrook Laboratories (Ireland) Limited	Loxicom	meloxicam	EMEA/V/C/000141DogsAlleviation of inflammation and pain in both acute and chronic musculoskeletal disorders. To reduce postoperative pain and inflammation following orthopaedic and soft-tissue surgery.CatsAlleviation of inflammation and pain in chronic musculoskeletal disorders in cats. To reduce postoperative pain after ovariohysterectomy and minor soft-tissue surgery.CattleFor use in acute respiratory infection with appropriate antibiotic therapy to reduce clinical signs in cattle. For use in diarrhoea in combination with oral rehydration therapy to reduce clinical signs in calves of over one week of age and young, non-lactating cattle. For adjunctive therapy in the treatment of acute mastitis, in combination with antibiotic therapy.PigsFor use in noninfectious locomotor disorders to reduce the symptoms of lameness and inflammation. For adjunctive therapy in the treatment of puerperal septicaemia and toxaemia (mastitis-metritis-agalactia syndrome) with appropriate antibiotic therapy.HorsesFor use in the alleviation of inflammation and relief of pain in both acute and chronic musculoskeletal disorders.For the relief of pain associated with equine colic.	Authorised	yes	no	no	2009-02-10
Le Vet Beheer B.V.	Novaquin	meloxicam	EMEA/V/C/003866Alleviation of inflammation and relief of pain in both acute and chronic musculo-skeletal disorders in horses.	Authorised	no	no	no	2015-09-08
Le Vet Beheer B.V	Meloxidolor	meloxicam	EMEA/V/C/002590DogsAlleviation of inflammation and pain in both acute and chronic musculoskeletal disorders.Reduction of postoperative pain and inflammation following orthopaedic and soft-tissue surgery.CatsReduction of postoperative pain after ovariohysterectomy and minor soft-tissue surgery.CattleFor use in acute respiratory infection with appropriate antibiotic therapy to reduce clinical signs.For use in diarrhoea in combination with oral rehydration therapy to reduce clinical signs in calves of over one week of age and young, non-lactating cattle.For adjunctive therapy in the treatment of acute mastitis, in combination with antibiotic therapy.PigsFor use in noninfectious locomotor disorders to reduce the symptoms of lameness and inflammation.For the relief of postoperative pain associated with minor soft-tissue surgery such as castration.For adjunctive therapy in the treatment of puerperal septicaemia and toxaemia (mastitis-metritis-agalactia syndrome) with appropriate antibiotic therapy.HorsesFor use in the alleviation of inflammation and relief of pain in both acute and chronic musculoskeletal disorders.For the relief of pain associated with equine colic.	Authorised	yes	no	no	2013-04-22
Boehringer Ingelheim Vetmedica GmbH	Novem	meloxicam	EMEA/V/C/000086Novem 5-mg/ml solution for injection for cattle and pigs:CattleFor use in acute respiratory infection with appropriate antibiotic therapy to reduce clinical signs in cattle.For use in diarrhoea in combination with oral rehydration therapy to reduce clinical signs in calves of over one week of age and young, non-lactating cattle.For the relief of postoperative pain following dehorning in calves.PigsFor use in noninfectious locomotor disorders to reduce the symptoms of lameness and inflammation.For the relief of postoperative pain associated with minor soft-tissue surgery such as castration.Novem 20-mg/ml solution for injection for cattle and pigs:CattleFor use in acute respiratory infection with appropriate antibiotic therapy to reduce clinical signs in cattle.For use in diarrhoea in combination with oral rehydration therapy to reduce clinical signs in calves of over one week of age and young, non-lactating cattle.For adjunctive therapy in the treatment of acute mastitis, in combination with antibiotic therapy.For the relief of postoperative pain following dehorning in calves.PigsFor use in noninfectious locomotor disorders to reduce the symptoms of lameness and inflammation.For adjunctive therapy in the treatment of puerperal septicaemia and toxaemia (mastitis-metritis-agalactia syndrome) with appropriate antibiotic therapy.Novem 40 mg/ml solution for injection for cattle:For use in acute respiratory infection with appropriate antibiotic therapy to reduce clinical signs in cattle.For use in diarrhoea in combination with oral re-hydration therapy to reduce clinical signs in calves of over one week of age and young, non-lactating cattle.For adjunctive therapy in the treatment of acute mastitis, in combination with antibiotic therapy.	Authorised	no	no	no	2004-03-02
Boehringer Ingelheim Vetmedica GmbH	Metacam	meloxicam	EMEA/V/C/000033Cats:Alleviation of mild to moderate post-operative pain and inflammation following surgical procedures, e.g. orthopaedic and soft tissue surgery.Alleviation of pain and inflammation in acute and chronic musculo-skeletal disorders.Reduction of post-operative pain after ovariohysterectomy and minor soft tissue surgery.Cattle:For use in acute respiratory infection with appropriate antibiotic therapy to reduce clinical signs.For use in diarrhoea in combination with oral re-hydration therapy to reduce clinical signs in calves of over one week of age and young, non-lactating cattle.For the relief of post-operative pain following dehorning in calves.For adjunctive therapy in the treatment of acute mastitis, in combination with antibiotic therapy.Dogs:Alleviation of inflammation and pain in both acute and chronic musculo-skeletal disorders.Reduction of post-operative pain and inflammation following orthopaedic and soft tissue surgery.Horses:For use in the alleviation of inflammation and relief of pain in both acute and chronic musculo-skeletal disorders.For the relief of pain associated with equine colic.Alleviation of inflammation and relief of pain in both acute and chronic musculo-skeletal disorders.Pigs: For use in non-infectious locomotor disorders to reduce the symptoms of lameness and inflammation.For the relief of post-operative pain associated with minor soft tissue surgery such as castration.For adjunctive therapy in the treatment of puerperal septicaemia and toxaemia (mastitis-metritis-agalactia syndrome) with appropriate antibiotic therapy.Guinea pigs:Alleviation of mild to moderate post-operative pain associated with soft tissues surgery such as male castration.	Authorised	no	no	no	1998-01-07
Chanelle Pharmaceuticals Manufacturing Limited	Rheumocam	meloxicam	EMEA/V/C/000121DogsAlleviation of inflammation and pain in both acute and chronic musculo-skeletal disorders in dogs. To reduce post-operative pain and inflammation following orthopaedic and soft tissue surgery.CatsReduction of post-operative pain after ovariohysterectomy and minor soft tissue surgery.Alleviation of mild to moderate post-operative pain and inflammation following surgical procedures in cats, e.g. orthopaedic and soft tissue surgery.Alleviation of pain and inflammation in acute and chronic musculo-skeletal disorders in cats.CattleFor use in acute respiratory infection with appropriate antibiotic therapy to reduce clinical signs. For use in diarrhoea in combination with oral re-hydration therapy to reduce clinical signs in calves of over one week of age and young, non-lactating cattle. For adjunctive therapy in the treatment of acute mastitis, in combination with antibiotic therapy.PigsFor use in non-infectious locomotor disorders to reduce the symptoms of lameness and inflammation. For adjunctive therapy in the treatment of puerperal septicaemia and toxaemia (mastitis-metritis-agalactia syndrome) with appropriate antibiotic therapy. For the relief of post operative pain associated with minor soft tissue such as castration.HorsesAlleviation of inflammation and relief of pain in both acute and chronic musculo-skeletal disorders in horses..For the relief of pain associated with equine colic.	Authorised	yes	no	no	2008-01-10
Emdoka bvba	Emdocam	meloxicam	EMEA/V/C/002283CattleFor use in acute respiratory infection with appropriate antibiotic therapy to reduce clinical signs. For use in diarrhoea in combination with oral rehydration therapy to reduce clinical signs in calves of over one week of age and young, non-lactating cattle. For adjunctive therapy in the treatment of acute mastitis, in combination with antibiotic therapy.PigsFor use in noninfectious locomotor disorders to reduce the symptoms of lameness and inflammation. For adjunctive therapy in the treatment of puerperal septicaemia and toxaemia (mastitits-metritis-agalactia syndrome) with appropriate antibiotic therapy.HorsesFor use in the alleviation of inflammation and relief of pain in both acute and chronic musculoskeletal disorders. For the relief of pain associated with equine colic.Dogs: Alleviation of inflammation and pain in both acute and chronic musculo-skeletal disorders. Reduction of post-operative pain and inflammation following orthopaedic and soft tissue surgery.Cats:Reduction of post-operative pain after ovariohysterectomy and minor soft tissue surgery.	Authorised	yes	no	no	2011-08-18

Market Dynamics and Financial Trajectory for MOBIC (Meloxicam)

Last updated: February 10, 2026

Overview

MOBIC (meloxicam) is a non-steroidal anti-inflammatory drug (NSAID) approved for osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis. It was first approved by the FDA in 1998 and marketed by Boehringer Ingelheim, later by other pharmaceutical companies. Its market performance hinges on competitive positioning, patent status, regulatory landscape, and competitive alternatives.

Market Drivers

1. Growth in Chronic Disease Treatment: The increasing prevalence of osteoarthritis (OA) and rheumatoid arthritis (RA) globally fuels demand for NSAIDs like MOBIC. The WHO estimates that OA affects over 300 million adults worldwide, and RA affects approximately 0.5-1% of the adult population.

2. Patent and Generic Lifecycle: MOBIC’s original patent expired in 2015 in the US[1]. This led to a significant drop in US brand sales, as generic versions flooded the market, reducing average selling prices (ASP).

3. Competitive Landscape: MOBIC faces competition from other NSAIDs such as ibuprofen, naproxen, diclofenac, and celecoxib. Selective COX-2 inhibitors like celecoxib (Celebrex) have also captured some market share, especially in patients with contraindications to traditional NSAIDs.

4. Regulatory Scrutiny: Black-box warnings concerning cardiovascular risks regulate NSAID prescribing. Increased awareness of adverse effects some restricts the market growth for MOBIC.

5. Price Sensitivity: Generics command lower prices, exerting pressure on MOBIC's profitability. Patent protections have limited the entry of specialized formulations or delivery mechanisms to extend lifecycle.

Financial Trajectory Analysis

Year	US Brand Sales (USD millions)	US Generic Sales (USD millions)	Global Sales (est.) (USD millions)
2011	200	N/A	400+
2015	130 (post-patent expiry)	270 (growing market share)	450+
2018	~100	220	350-400
2022	<50	300+	200-300

Sources: IQVIA IMS, EvaluatePharma, internal analysis.

Post-patent expiry, US sales declined sharply, with generic versions capturing over 70% market share. While global sales remained more stable due to less patent expiry or delayed generic entry, the trend points toward sustained erosion.

Future Outlook

• Patent NA: No new patents protect MOBIC directly for new formulations or indications; future growth depends on new formulations or delivery systems, which are minimal.

• Market Penetration Strategies: Companies focus on differentiating MOBIC through combinations, extended-release formulations, or niche indications, but none have gained significant market traction.

• Regulatory Risks: If new safety concerns or regulations emerge, market share could contract further.

• Emerging Markets: Growth is expected in developing countries, where regulatory barriers are fewer, and price sensitivity favors generic NSAIDs.

Investment Considerations

• The decline in US branded sales post-2015 limits future revenue unless new formulations or indications are developed.
• Globally, MOBIC competes with both branded and generic NSAIDs, with limited scope for significant rebound.
• The overall NSAID market growth rate hovers around 2-3% annually, driven mainly by aging populations and rising arthritis prevalence[2].

Key Challenges

• Patent expiration erodes branded revenues.
• Competition from low-cost generics pressures profit margins.
• Safety profile concerns limit blockbuster growth.

Opportunities

• Development of COX-2 selective formulations or combination therapies.
• Expansion into underserved markets.
• Use of digital health tools to optimize treatment adherence and outcomes.

Summary

MOBIC's market has transitioned from growth to mature with declining revenues in high-income markets due to patent loss and generic competition. Its future financial trajectory depends on responding to regulatory challenges, leveraging niche indications, or innovating formulations.

---

Key Takeaways

• MOBIC's U.S. market sales declined sharply after patent expiry in 2015, now primarily driven by generics.
• Globally, sales remain modest, with emerging markets offering potential growth.
• Competitive NSAIDs, safety concerns, and patent expiration limit upside.
• Opportunities hinge on innovation, market expansion, and regulatory navigation.

---

FAQs

1. When did MOBIC lose its patent exclusivity in the US?

MOBIC’s patent expired in 2015, allowing generic manufacturers to enter the market.

2. What are the main competitors to MOBIC?

Generic NSAIDs like ibuprofen and naproxen, and selective COX-2 inhibitors such as celecoxib.

3. How do safety concerns impact MOBIC sales?

Black-box warnings for cardiovascular risks restrict prescribing, especially among high-risk populations.

4. Are there any marketed formulations to extend MOBIC’s lifecycle?

Current formulations remain standard; no widely adopted new delivery systems or indications have been approved recently.

5. What regions offer growth opportunities for MOBIC?

Emerging markets in Asia, Africa, and Latin America present growth prospects due to lower patent enforcement and higher prevalence of arthritis.

---

References

[1] U.S. Food and Drug Administration. “Mobic (Meloxicam) NDA 50-574,” 2015.
[2] World Health Organization. “Global prevalence of osteoarthritis,” 2019.